Literature DB >> 26207162

Hepatic metastatic disease in pediatric and adolescent solid tumors.

Israel Fernandez-Pineda1, John A Sandoval1, Andrew M Davidoff1.   

Abstract

The management of hepatic metastatic disease from solid tumors in adults has been extensively described and resection of metastatic liver lesions from colorectal adenocarcinoma, renal adenocarcinoma, breast cancer, testicular cancer, and neuroendocrine tumors (NET) have demonstrated therapeutic benefits in select patients. However, there are few reports in the literature on the management of hepatic metastatic disease in the pediatric and adolescent populations and the effectiveness of hepatic metastasectomy. This may be due to the much lower incidence of pediatric malignancies and the higher chemosensitivity of childhood tumors which make hepatic metastasectomy less likely to be required. We review liver involvement with metastatic disease from the main pediatric solid tumors, including neuroblastoma and Wilms tumor focusing on the management and treatment options. We also review other solid malignant tumors which may have liver metastases including germ cell tumors, gastrointestinal stromal tumors, osteosarcoma, desmoplastic small round cell tumors and NET. However, these histological subtypes are so rare in the pediatric and adolescent populations that the exact incidence and best management of hepatic metastatic disease are unknown and can only be extrapolated from adult series.

Entities:  

Keywords:  Hepatic metastatic disease; Neuroblastoma; Pediatric and adolescent solid tumors; Wilms tumor

Year:  2015        PMID: 26207162      PMCID: PMC4506938          DOI: 10.4254/wjh.v7.i14.1807

Source DB:  PubMed          Journal:  World J Hepatol


  107 in total

1.  [Liver metastasis of breast carcinoma. Results of surgical resection. Analysis of 15 operated cases].

Authors:  E Santoro; C Vitucci; M Carlini; F Carboni; E Santoro; M Sacchi; A Calisti; P Lepiane
Journal:  Chir Ital       Date:  2000 Mar-Apr

2.  A case-control study of risk factors for hepatoblastoma. A report from the Childrens Cancer Study Group.

Authors:  J D Buckley; H Sather; K Ruccione; P C Rogers; J E Haas; B E Henderson; G D Hammond
Journal:  Cancer       Date:  1989-09-01       Impact factor: 6.860

Review 3.  Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis.

Authors:  Zoltan Máthé; Evangelos Tagkalos; Andreas Paul; Ernesto P Molmenti; László Kóbori; Ioannis Fouzas; Susanne Beckebaum; Georgios C Sotiropoulos
Journal:  Transplantation       Date:  2011-03-15       Impact factor: 4.939

4.  International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.

Authors:  H Shimada; S Umehara; Y Monobe; Y Hachitanda; A Nakagawa; S Goto; R B Gerbing; D O Stram; J N Lukens; K K Matthay
Journal:  Cancer       Date:  2001-11-01       Impact factor: 6.860

5.  Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival.

Authors:  S G DuBois; Y Kalika; J N Lukens; G M Brodeur; R C Seeger; J B Atkinson; G M Haase; C T Black; C Perez; H Shimada; R Gerbing; D O Stram; K K Matthay
Journal:  J Pediatr Hematol Oncol       Date:  1999 May-Jun       Impact factor: 1.289

6.  The clinical course in pediatric solid tumor patients with focal nodular hyperplasia of the liver.

Authors:  Kiminobu Sugito; Shota Uekusa; Hiroyuki Kawashima; Takeshi Furuya; Kensuke Ohashi; Mikiya Inoue; Taro Ikeda; Tsugumichi Koshinaga; Ryouichi Tomita; Hideo Mugishima; Toshiya Maebayashi
Journal:  Int J Clin Oncol       Date:  2011-04-01       Impact factor: 3.402

7.  Late recurrence of neuroblastoma stage 4S with unusual clinicopathologic findings.

Authors:  K Kato; K Ishikawa; Y Toyoda; H Kigasawa; N Aida; T Nishi; T Kusafuka; J Hara ; R Ijiri; Y Tanaka
Journal:  J Pediatr Surg       Date:  2001-06       Impact factor: 2.545

8.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

9.  Prognostic factor in neuroblastoma.

Authors:  A E Evans; G J D'Angio; K Propert; J Anderson; H W Hann
Journal:  Cancer       Date:  1987-06-01       Impact factor: 6.860

10.  Treatment of stage 4s neuroblastoma--report of 10 years' experience of the French Society of Paediatric Oncology (SFOP).

Authors:  G Schleiermacher; H Rubie; O Hartmann; C Bergeron; P Chastagner; F Mechinaud; J Michon
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

View more
  4 in total

Review 1.  Magnetic resonance imaging features of common focal liver lesions in children.

Authors:  Prakash M Masand
Journal:  Pediatr Radiol       Date:  2018-08-04

2.  Clinical and biological features of neuroblastic tumors: A comparison of neuroblastoma and ganglioneuroblastoma.

Authors:  Wen-Guang He; Yu Yan; Wen Tang; Rong Cai; Gang Ren
Journal:  Oncotarget       Date:  2017-06-06

3.  Radiological staging in neuroblastoma: computed tomography or magnetic resonance imaging?

Authors:  Fatma C Sarioglu; Muhammet Salman; Handan Guleryuz; Erdener Ozer; Emre Cecen; Dilek Ince; Nur Olgun
Journal:  Pol J Radiol       Date:  2019-01-18

4.  Collagen 1A1 (COL1A1) Is a Reliable Biomarker and Putative Therapeutic Target for Hepatocellular Carcinogenesis and Metastasis.

Authors:  Hon-Ping Ma; Hang-Lung Chang; Oluwaseun Adebayo Bamodu; Vijesh Kumar Yadav; Ting-Yi Huang; Alexander T H Wu; Chi-Tai Yeh; Shin-Han Tsai; Wei-Hwa Lee
Journal:  Cancers (Basel)       Date:  2019-06-07       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.